2020
DOI: 10.1016/j.euroneuro.2020.05.004
|View full text |Cite
|
Sign up to set email alerts
|

Pimavanserin exhibits serotonin 5-HT2A receptor inverse agonism for Gαi1- and neutral antagonism for Gαq/11-proteins in human brain cortex

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
27
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 30 publications
(27 citation statements)
references
References 26 publications
0
27
0
Order By: Relevance
“…Additionally, for these receptor subtypes, biased agonism was demonstrated. This phenomenon results in activation of different signal pathways depending on ligand [ 24 , 264 , 265 , 266 ]. At the same time, for 5-HT 2C receptors, mRNA-editing resulting in the translation of various isoforms of receptor was shown [ 267 , 268 , 269 ].…”
Section: Discussionmentioning
confidence: 99%
“…Additionally, for these receptor subtypes, biased agonism was demonstrated. This phenomenon results in activation of different signal pathways depending on ligand [ 24 , 264 , 265 , 266 ]. At the same time, for 5-HT 2C receptors, mRNA-editing resulting in the translation of various isoforms of receptor was shown [ 267 , 268 , 269 ].…”
Section: Discussionmentioning
confidence: 99%
“…This is of note due to the fact that it can be used as a precursor of serotonin in the human body. Thus, it is thought to help increase the levels of serotonin, which plays an important role in the treatment of depression in humans [24]. However, further exploration is needed to study the regulatory mechanism and function involved in fruit splitting.…”
Section: Discussionmentioning
confidence: 99%
“…The discovery that 5-HT2A receptor inverse agonists have antipsychotic effects opened an alternative pathway for treating psychosis and drove the development of pimavanserin, a 5HT2A inverse agonist. Pimavanserin lacks dopamine receptor affinity but exhibits antipsychotic activity [ 65 ]. In 2016, the FDA and EMA approved pimavanserin for the treatment of psychosis in Parkinson’s disease.…”
Section: Serotonin In the Gi Tractmentioning
confidence: 99%